Zechen Biotechnology, founded in August 2011 in Jiangsu, develops in-vitro diagnostic instruments and reagents with a core focus on fully automated chemiluminescence products and POCT devices, supplemented by high-value biochemical products. The company has launched multiple upgraded chemiluminescence products, including the high-throughput CIA2800, compact POCT chemiluminescence instruments, and biochemical analyzers. Its products are used by more than a thousand institutions. Zechen reports a portfolio of proprietary intellectual property across core raw materials (magnetic beads, substrates, antibodies), small-molecule labeling technologies, reagent kit methodologies, and instrument automation control. The company's product lineup positions POCT as a key area of emphasis alongside automated chemiluminescence. Financially, the company completed a C round financing in 2019 (see deal details).

Total raised

$26M

Funding rounds

1

Latest round

Series C

Latest activity

Jul 2019